Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
5.4
Journals
Pharmaceutics
Special Issues
Peptide-Based Carriers for Drug Delivery
share announcement

Peptide-Based Carriers for Drug Delivery

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: closed (29 February 2024) | Viewed by 3953

Special Issue Editor

Prof. Dr. Jeng-Shiung Jan

E-Mail Website
Guest Editor
Department of Chemical Engineering, National Cheng Kung University, No.1, University Road, Tainan 701401, Taiwan
Interests: polypeptides; hydrogels; nanogels; antibacterial/anticancer peptides; peptide-based carriers

Special Issue Information

Dear Colleagues,

This Special Issue will focus on the latest progress of novel polypeptide-based hydrogels/nanogels as carriers for delivering therapeutic drugs. In recent years, a variety of polymer-based hydrogels/nanogels have been studied extensively for biomedical applications, including drug delivery and tissue engineering. These hydrogels/nanogels can stimulate structural and/or morphological responses in response to the changes in environmental conditions. Synthetic polymer-based hydrogels/nanogels have exhibited versatility in tailoring macromolecular chemistry to tune the material properties and functionality as compared to their natural counterparts. Polypeptide-based hydrogels/nanogels are particularly of interest due to their biocompatible/biodegradable building blocks and essential structure–function relationship, endowing them with biofunctionality and self-assembly versatility. We anticipate contributions from scientists working on the development of polypeptide-based hydrogels/nanogels for drug delivery, which could be investigated in several diseases using in vitro assays and/or in vivo animal models.

Prof. Dr. Jeng-Shiung Jan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • peptide
  • hydrogel
  • nanogel
  • stimuli-responsive properties
  • therapeutic drugs (chemodrugs, siRNA, miRNA, etc.)

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

20 pages, 2311 KiB  
Article
LDLR-Mediated Targeting and Productive Uptake of siRNA-Peptide Ligand Conjugates In Vitro and In Vivo
by Baptiste Broc, Karine Varini, Rose Sonnette, Belinda Pecqueux, Florian Benoist, Maxime Masse, Yasmine Mechioukhi, Géraldine Ferracci, Jamal Temsamani, Michel Khrestchatisky, Guillaume Jacquot and Pascaline Lécorché
Pharmaceutics 2024, 16(4), 548; https://doi.org/10.3390/pharmaceutics16040548 - 17 Apr 2024
Viewed by 348
Abstract
Small RNA molecules such as microRNA and small interfering RNA (siRNA) have become promising therapeutic agents because of their specificity and their potential to modulate gene expression. Any gene of interest can be potentially up- or down-regulated, making RNA-based technology the healthcare breakthrough [...] Read more.
Small RNA molecules such as microRNA and small interfering RNA (siRNA) have become promising therapeutic agents because of their specificity and their potential to modulate gene expression. Any gene of interest can be potentially up- or down-regulated, making RNA-based technology the healthcare breakthrough of our era. However, the functional and specific delivery of siRNAs into tissues of interest and into the cytosol of target cells remains highly challenging, mainly due to the lack of efficient and selective delivery systems. Among the variety of carriers for siRNA delivery, peptides have become essential candidates because of their high selectivity, stability, and conjugation versatility. Here, we describe the development of molecules encompassing siRNAs against SOD1, conjugated to peptides that target the low-density lipoprotein receptor (LDLR), and their biological evaluation both in vitro and in vivo. Full article
(This article belongs to the Special Issue Peptide-Based Carriers for Drug Delivery)
►▼ Show Figures

Figure 1

27 pages, 4163 KiB  
Article
Optimization of Statin-Loaded Delivery Nanoparticles for Treating Chronic Liver Diseases by Targeting Liver Sinusoidal Endothelial Cells
by Mar Gil, Lareen Khouri, Imma Raurell, Diana Rafael, Fernanda Andrade, Ibane Abasolo, Simo Schwartz, Jr., María Martínez-Gómez, María Teresa Salcedo, Juan Manuel Pericàs, Diana Hide, Mingxing Wei, Norman Metanis, Joan Genescà and María Martell
Pharmaceutics 2023, 15(10), 2463; https://doi.org/10.3390/pharmaceutics15102463 - 14 Oct 2023
Viewed by 1750
Abstract
In this study, we developed functionalized polymeric micelles (FPMs) loaded with simvastatin (FPM-Sim) as a drug delivery system to target liver sinusoidal endothelial cells (LSECs) for preserving liver function in chronic liver disease (CLD). Polymeric micelles (PMs) were functionalized by coupling peptide ligands [...] Read more.
In this study, we developed functionalized polymeric micelles (FPMs) loaded with simvastatin (FPM-Sim) as a drug delivery system to target liver sinusoidal endothelial cells (LSECs) for preserving liver function in chronic liver disease (CLD). Polymeric micelles (PMs) were functionalized by coupling peptide ligands of LSEC membrane receptors CD32b, CD36 and ITGB3. Functionalization was confirmed via spectroscopy and electron microscopy. In vitro and in vivo FPM-Sim internalization was assessed by means of flow cytometry in LSECs, hepatocytes, Kupffer and hepatic stellate cells from healthy rats. Maximum tolerated dose assays were performed in healthy mice and efficacy studies of FPM-Sim were carried out in bile duct ligation (BDL) and thioacetamide (TAA) induction rat models of cirrhosis. Functionalization with the three peptide ligands resulted in stable formulations with a greater degree of in vivo internalization in LSECs than non-functionalized PMs. Administration of FPM-Sim in BDL rats reduced toxicity relative to free simvastatin, albeit with a moderate portal-pressure-lowering effect. In a less severe model of TAA-induced cirrhosis, treatment with FPM-CD32b-Sim nanoparticles for two weeks significantly decreased portal pressure, which was associated with a reduction in liver fibrosis, lower collagen expression as well as the stimulation of nitric oxide synthesis. In conclusion, CD32b-FPM stands out as a good nanotransporter for drug delivery, targeting LSECs, key inducers of liver injury. Full article
(This article belongs to the Special Issue Peptide-Based Carriers for Drug Delivery)
►▼ Show Figures

Graphical abstract

20 pages, 5109 KiB  
Article
Sustained Release of Tacrolimus Embedded in a Mixed Thermosensitive Hydrogel for Improving Functional Recovery of Injured Peripheral Nerves in Extremities
by Aline Yen Ling Wang, Kuan-Hung Chen, Hsiu-Chao Lin, Charles Yuen Yung Loh, Yun-Ching Chang, Ana Elena Aviña, Chin-Ming Lee, I-Ming Chu and Fu-Chan Wei
Pharmaceutics 2023, 15(2), 508; https://doi.org/10.3390/pharmaceutics15020508 - 03 Feb 2023
Cited by 2 | Viewed by 1407
Abstract
Vascularized composite allotransplantation is an emerging strategy for the reconstruction of unique defects such as amputated limbs that cannot be repaired with autologous tissues. In order to ensure the function of transplanted limbs, the functional recovery of the anastomosed peripheral nerves must be [...] Read more.
Vascularized composite allotransplantation is an emerging strategy for the reconstruction of unique defects such as amputated limbs that cannot be repaired with autologous tissues. In order to ensure the function of transplanted limbs, the functional recovery of the anastomosed peripheral nerves must be confirmed. The immunosuppressive drug, tacrolimus, has been reported to promote nerve recovery in animal models. However, its repeated dosing comes with risks of systemic malignancies and opportunistic infections. Therefore, drug delivery approaches for locally sustained release can be designed to overcome this issue and reduce systemic complications. We developed a mixed thermosensitive hydrogel (poloxamer (PLX)-poly(l-alanine-lysine with Pluronic F-127) for the time-dependent sustained release of tacrolimus in our previous study. In this study, we demonstrated that the hydrogel drug degraded in a sustained manner and locally released tacrolimus in mice over one month without affecting the systemic immunity. The hydrogel drug significantly improved the functional recovery of injured sciatic nerves as assessed using five-toe spread and video gait analysis. Neuroregeneration was validated in hydrogel–drug-treated mice using axonal analysis. The hydrogel drug did not cause adverse effects in the mouse model during long-term follow-up. The local injection of encapsulated-tacrolimus mixed thermosensitive hydrogel accelerated peripheral nerve recovery without systemic adverse effects. Full article
(This article belongs to the Special Issue Peptide-Based Carriers for Drug Delivery)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop